Why this seasoned money manager sees real upside for this innovative B2B tech startup. on 10/26/2021. Learn More

Sector Expert: Bernard Siegel

Genetics Policy Institute

Image: Bernard Siegel

Bernard Siegel is the founder and executive director of Genetics Policy Institute (GPI). He is also the founder and co-chair of a series of global conferences, including the annual World Stem Cell Summit, and founder and editor-in-chief of the peer-reviewed World Stem Cell Report. Siegel first became involved with the scientific community when, in 2002, he filed a landmark case seeking a guardian for the alleged clone, "Baby Eve." This case, and the media attention which ensued, allowed Siegel to meet with scientists and policy experts to discuss the need for legal and policy advocates for the scientific community. This led to Siegel's founding of the Genetics Policy Institute and his commitment to advocacy work on behalf of patients, doctors and researchers involved with the regenerative medicine community. Siegel is a native of Richmond, Virginia. He received his undergraduate and law degrees from the University of Miami and has been a member of the Florida Bar since 1975.

Recent Interviews

Advocacy and Technology Move Stem Cell Research Forward: Bernie Siegel of the Genetics Policy Institute (10/7/15)

Regenerative medicine through stem cell technology is a source of hope for many suffering from ailments including Alzheimer's disease, diabetes, spinal cord injury and cancer. While new therapeutic options are continually in development, progress has, until recently, been hampered by political and medical ethics arguments. Because of patient advocacy, new technologies are now advancing, from development of an artificial pancreas to the hope of culturing intact human organs. In this interview with The Life Sciences Report, Bernie Siegel, founder and executive director of the Genetics Policy Institute, describes recent progress and developments in the regenerative medicine universe.

Recent Quotes

"STEM is a pioneering company dealing with the challenges of cell therapies."

The Life Science Report Interview with Bernie Siegel (10/7/15)
more >

Due to permission requirements, not all quotes are shown.